Targeting N-cadherin switching holds excellent potential for developing effective therapeutic interventions to prevent or treat lymph node metastasis, ultimately improving oral cancer patients’ survival rates and quality of life. Here, CDH2 is linked to lip and oral cavity carcinoma.